Publication

Once daily versus twice-daily radiotherapy in the management of limited disease small cell lung cancer - Decision criteria in routine practise

Journal Paper/Review - May 22, 2020

Units
Keywords
PubMed
Doi
Link
Contact

Citation
Glatzer M, Faivre-Finn C, De Ruysscher D, Widder J, Van Houtte P, Troost E, Dahele M, Slotman B, Ramella S, Pöttgen C, Peeters S, Nestle U, McDonald F, Le Pechoux C, Dziadziuszko R, Belderbos J, Putora P. Once daily versus twice-daily radiotherapy in the management of limited disease small cell lung cancer - Decision criteria in routine practise. Radiother Oncol 2020; 150:26-29.
Project
Type
Journal Paper/Review (English)
Journal
Radiother Oncol 2020; 150
Publication Date
May 22, 2020
Issn Print
Issn Electronic
1879-0887
Pages
26-29
Publisher
Brief description/objective

BACKGROUND
In limited disease small cell lung cancer (LD-SCLC), the CONVERT trial has not demonstrated superiority of once-daily (QD) radiotherapy (66 Gy) over twice-daily (BID) radiotherapy (45 Gy). We explored the factors influencing the selection between QD and BID regimens.

METHODS
Thirteen experienced European thoracic radiation oncologists as selected by the European Society for Therapeutic Radiation Oncology (ESTRO) were asked to describe their strategies in the management of LD-SCLC. Treatment strategies were subsequently converted into decision trees and analysed for agreement and discrepancies.

RESULTS
Logistic reasons, patients' performance status and radiotherapy dose constraints were the three major decision criteria used by most experts in decision making. The use of QD and BID regimens was balanced among European experts, but there was a trend towards the BID regimen for fit patients able to travel twice a day to the radiotherapy site.

CONCLUSION
BID and QD radiotherapy are both accepted regimens among experts and the decision is influenced by pragmatic factors such as availability of transportation.